retatrutide approval status 2025 retatrutide fda approval glp-1 reta Retatrutide, an experimental weight-loss drug, has not been approved by the This weight-loss drug hasn't been

10.1002/mnfr.202400227 35 KanwalF.KramerJ

Thyroid dysfunction associated with iodine-contrast media: A real-world pharmacovigilance study based on the FDA adverse event reporting system

For people coming off other GLP-1s (semaglutide or tirzepatide), you have some receptor adaptation already

As we age or face environmental stressors, our natural levels of this essential compound often begin to decline

Nonsurgical fat reduction

Until we have better data, the decision whether to hold GLP-1 agonists or not seems to primarily come down to balancing the estimated risk of hyperglycemia of stopping them versus the risk of aspiration without stopping them